Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale

Abstract Cognitive functioning can be assessed with performance-based assessments such as neuropsychological tests and with interview-based assessments. Both assessment methods have the potential to assess whether treatments for schizophrenia improve clinically relevant aspects of cognitive impairme...

Full description

Saved in:
Bibliographic Details
Published in:European neuropsychopharmacology 2015-02, Vol.25 (2), p.176-184
Main Authors: Keefe, Richard S.E, Davis, Vicki G, Spagnola, Nathan B, Hilt, Dana, Dgetluck, Nancy, Ruse, Stacy, Patterson, Thomas D, Narasimhan, Meera, Harvey, Philip D
Format: Article
Language:English
Subjects:
Adult
alpha7 Nicotinic Acetylcholine Receptor - agonists
Antipsychotic Agents - therapeutic use
Assessment
Cognition
Cognition - drug effects
Cognition Disorders - diagnosis
Cognition Disorders - physiopathology
Cognitive impairment
Europe
Factor Analysis, Statistical
Female
Humans
Internal Medicine
Interview, Psychological - methods
Male
Psychiatric Status Rating Scales
Psychiatry
Psychometrics
Reproducibility of Results
Schizophrenia
Schizophrenia - diagnosis
Schizophrenia - drug therapy
Schizophrenia - physiopathology
Schizophrenic Psychology
SCoRS
Sensitivity and Specificity
Treatment response
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Cognitive functioning can be assessed with performance-based assessments such as neuropsychological tests and with interview-based assessments. Both assessment methods have the potential to assess whether treatments for schizophrenia improve clinically relevant aspects of cognitive impairment. However, little is known about the reliability, validity and treatment responsiveness of interview-based measures, especially in the context of clinical trials. Data from two studies were utilized to assess these features of the Schizophrenia Cognition Rating Scale (SCoRS). One of the studies was a validation study involving 79 patients with schizophrenia assessed at 3 academic research centers in the US. The other study was a 32-site clinical trial conducted in the US and Europe comparing the effects of encenicline, an alpha-7 nicotine agonist, to placebo in 319 patients with schizophrenia. The SCoRS interviewer ratings demonstrated excellent test-retest reliability in several different circumstances, including those that did not involve treatment (ICC> 0.90), and during treatment (ICC>0.80). SCoRS interviewer ratings were related to cognitive performance as measured by the MCCB ( r =−0.35), and demonstrated significant sensitivity to treatment with encenicline compared to placebo ( P
ISSN:0924-977X
1873-7862
DOI:10.1016/j.euroneuro.2014.06.009